BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22090274)

  • 1. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome.
    Lungu AO; Zadeh ES; Goodling A; Cochran E; Gorden P
    J Clin Endocrinol Metab; 2012 Feb; 97(2):563-7. PubMed ID: 22090274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance.
    Huang-Doran I; Kinzer AB; Jimenez-Linan M; Thackray K; Harris J; Adams CL; de Kerdanet M; Stears A; O'Rahilly S; Savage DB; Gorden P; Brown RJ; Semple RK
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2367-2383. PubMed ID: 33901270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients.
    Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P
    Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
    Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P
    J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A; Patton L; De Iasio R; Palladoro F; Pagotto U; Pasquali R
    J Clin Endocrinol Metab; 2007 Jun; 92(6):2066-73. PubMed ID: 17356050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy.
    Oral EA; Ruiz E; Andewelt A; Sebring N; Wagner AJ; Depaoli AM; Gorden P
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3110-7. PubMed ID: 12107209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin resistance and hyperandrogenism have no substantive association with birth weight in adolescents with polycystic ovary syndrome.
    Fulghesu AM; Manca R; Loi S; Fruzzetti F
    Fertil Steril; 2015 Mar; 103(3):808-14. PubMed ID: 25637475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of rosiglitazone on insulin resistance and hyperandrogenism in polycystic ovary syndrome].
    Zheng Z; Li M; Lin Y; Ma Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):271-3. PubMed ID: 12133398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogenous origins of hyperandrogenism in the polycystic ovary syndrome in relation to body mass index and insulin resistance.
    Patlolla S; Vaikkakara S; Sachan A; Venkatanarasu A; Bachimanchi B; Bitla A; Settipalli S; Pathiputturu S; Sugali RN; Chiri S
    Gynecol Endocrinol; 2018 Mar; 34(3):238-242. PubMed ID: 29068242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
    Kolodziejczyk B; Duleba AJ; Spaczynski RZ; Pawelczyk L
    Fertil Steril; 2000 Jun; 73(6):1149-54. PubMed ID: 10856473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilateral Adrenal Hyperplasia as a Possible Mechanism for Hyperandrogenism in Women With Polycystic Ovary Syndrome.
    Gourgari E; Lodish M; Keil M; Sinaii N; Turkbey E; Lyssikatos C; Nesterova M; de la Luz Sierra M; Xekouki P; Khurana D; Ten S; Dobs A; Stratakis CA
    J Clin Endocrinol Metab; 2016 Sep; 101(9):3353-60. PubMed ID: 27336356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake and hyperandrogenemia in an obese rat model of polycystic ovary syndrome.
    Leblanc S; Battista MC; Noll C; Hallberg A; Gallo-Payet N; Carpentier AC; Vine DF; Baillargeon JP
    Endocrinology; 2014 Sep; 155(9):3684-93. PubMed ID: 24971613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leptin-replacement therapy for lipodystrophy.
    Oral EA; Simha V; Ruiz E; Andewelt A; Premkumar A; Snell P; Wagner AJ; DePaoli AM; Reitman ML; Taylor SI; Gorden P; Garg A
    N Engl J Med; 2002 Feb; 346(8):570-8. PubMed ID: 11856796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leptin concentrations in the polycystic ovary syndrome.
    Mantzoros CS; Dunaif A; Flier JS
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1687-91. PubMed ID: 9177364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
    Puurunen J; Piltonen T; Puukka K; Ruokonen A; Savolainen MJ; Bloigu R; Morin-Papunen L; Tapanainen JS
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4798-807. PubMed ID: 24152688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What have we learned form monogenic forms of severe insulin resistance associated with PCOS/HAIRAN?
    Vigouroux C
    Ann Endocrinol (Paris); 2010 May; 71(3):222-4. PubMed ID: 20362964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS.
    Shorakae S; Ranasinha S; Abell S; Lambert G; Lambert E; de Courten B; Teede H
    Clin Endocrinol (Oxf); 2018 Nov; 89(5):628-633. PubMed ID: 29992612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome.
    Moghetti P; Tosi F; Bonin C; Di Sarra D; Fiers T; Kaufman JM; Giagulli VA; Signori C; Zambotti F; Dall'Alda M; Spiazzi G; Zanolin ME; Bonora E
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E628-37. PubMed ID: 23476073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early metabolic derangements in daughters of women with polycystic ovary syndrome.
    Sir-Petermann T; Maliqueo M; Codner E; Echiburú B; Crisosto N; Pérez V; Pérez-Bravo F; Cassorla F
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4637-42. PubMed ID: 17848407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.